Sana Biotechnology

### Executive Summary Sana Biotechnology raised $770.6M via a Regulation D private placement, first sale date 2025-10-12, in synthetic biology and intracellular mRNA delivery. The filing lists Lockheed Martin Ventures and Bessemer Venture Partners as related persons, signaling strong institutional interest in a private-stage capital-intensive platform. ### Investor Edge Sophisticated investors should monitor for any subsequent Form D amendments (D/A) that reveal further capital tranches or pricing terms, as a raise this size often precedes a confidential IPO filing or major partnership announcement within 6–12 months. ### Sector capital positioning This massive $770.6M private raise in synthetic biology/mRNA delivery signals sustained large-cap private appetite for platform-based cell engineering, likely outpacing typical Series C or D rounds and reflecting confidence in manufacturing and delivery scale-up. ### Convergence Signals No explicit public patents, contracts, or legislation cited in the filing. However, Lockheed Martin Ventures' involvement may imply dual-use or government-adjacent interest in delivery technologies. ### Key Takeaways - $770.6M private capital raise in synthetic biology / intracellular mRNA delivery. - Lockheed Martin Ventures and Bessemer Venture Partners listed as related persons, indicating deep-tech and dual-use interest. - Form D notice filed first sale 10 months prior — suggests capital may have been deployed for R&D or manufacturing scale-up. ### Risk Indicators & Flags No D/A amendment filed yet; $770.6M is unusually large for a single private round, which may indicate aggressive cash burn or valuation risk. No public ticker or disclosed use of proceeds — limited transparency until next filing. ### Verification & References All data from SEC Form D accession 0001702600-24-20319; first sale date 2025-10-12; related persons Lockheed Martin Ventures and Bessemer Venture Partners; verify via SEC EDGAR company search for Sana Biotechnology.